NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NCT02743871

CompletedPhase 1

Sponsor: Pfizer

Conditions: Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis

Interventions: PF-06817024, Placebo for PF-06817024, PF-06817024, Placebo for PF-06817024, PF-06817024

Countries: United States

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with moderate-to-severe Atopic Dermatitis

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria

* Healthy male subjects, healthy female subjects of non-childbearing potential, 18-55 years of age (Part 1)
* Male subjects, female subjects of non-childbearing potential, female subjects of childbearing potential with documented bilateral tubal ligation (tubes tied) or bilateral salpingectomy (tubes removed), 18-65 years of age, and 2 of the following symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or reduction/loss of smell (Part 2)
* Male or female subjects between the ages of 18 and 75 years, inclusive with moderate-to-severe Atopic Dermatitis, agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps, or other ultraviolet light sources during the study (Part 3)

Exclusion Criteria:

* Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.), positive urine drug test, fever within 7 days of dosing, active infections within 28 days of dosing (Part 1 and 2 and 3)
* History of allergic reaction to topical lidocaine, nasal surgery within 6 months (Part 2)
* Exposure to live or attenuated vaccines, have skin conditions other than Atopic Dermatitis, use of JAK inhibitors and biologics (Part 3)

Locations (20)

Sacramento, California, United States
Sacramento, California, United States
Sacramento, California, United States
New Haven, Connecticut, United States
Shelton, Connecticut, United States
Tampa, Florida, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Plainfield, Indiana, United States
Edina, Minnesota, United States
Minneapolis, Minnesota, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
Berlin, New Jersey, United States
Raleigh, North Carolina, United States
Tulsa, Oklahoma, United States
Rapid City, South Dakota, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Norfolk, Virginia, United States